Evidence for phenotype-driven treatment in asthmatic patients

Current Opinion in Allergy and Clinical Immunology

Volumn 11, Issue 4, 2011, Pages 381-385

  Gonem, Sherif ^a   Desai, Dhananjay ^a   Siddiqui, Salman ^a   Brightling, Christopher C E ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

asthma; phenotype; stratified medicine

Indexed keywords

ADALIMUMAB; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; FLUTICASONE PROPIONATE PLUS SALMETEROL; GOLIMUMAB; IMMUNOGLOBULIN E; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 14; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 5; ITRACONAZOLE; MACROLIDE; MEPOLIZUMAB; MONOCLONAL ANTIBODY; NITRIC OXIDE; OMALIZUMAB; PITRAKINRA; PREDNISOLONE; SALMETEROL; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLERGIC ASTHMA; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; ASTHMA; BIOLOGICAL THERAPY; BRONCHOSPASM; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; DNA POLYMORPHISM; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; FUNGAL COLONIZATION; HUMAN; IMMUNE RESPONSE; LUNG FUNCTION; META ANALYSIS (TOPIC); MONOTHERAPY; MORTALITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY ASTHMA; RESPIRATORY TRACT ALLERGY; REVIEW; SEVERE PERSISTENT ASTHMA; SKIN TEST; SYSTEMATIC REVIEW (TOPIC);

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANTI-ASTHMATIC AGENTS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIFUNGAL AGENTS; ASTHMA; CELL COUNT; CHOLINERGIC ANTAGONISTS; EOSINOPHILS; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; LEUKOTRIENE ANTAGONISTS; PATIENT SELECTION; PHENOTYPE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPUTUM; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME;

EID: 79960836270     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328348a8f9     Document Type: Review

References (46)

1. Bousquet J, Mantzouranis E, Cruz A, et al, Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organisation consultation, J Allergy Clin Immunol 2010; 126:926-938.
2. British Thoracic Society, Scottish Intercollegiate Guidelines Network, British Guideline on the management of asthma, Thorax 2008; 63 (Suppl IV):1-121.
3. Haldar P, Pavord ID, Shaw DE, et al, Cluster analysis and clinical asthma phenotypes, Am J Respir Crit Care Med 2008; 178:218-224.
4. Moore WC, Meyers DA, Wenzel SE, et al, Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Programme, Am J Respir Crit Care Med 2010; 181:315-323.
5. Desai D, Siddiqui S, Brightling C, Can inhaled corticosteroids prevent asthma exacerbations? Curr Opin Pulm Med 2011; 17:16-22.
6. Green RH, Brightling CE, Woltmann G, et al, Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids, Thorax 2002; 57:875-879. (Pubitemid 35178612)
7. Berry M, Morgan A, Shaw DE, et al, Pathological features and inhaled corticosteroid response of eosinophilic and noneosinophilic asthma, Thorax 2007; 62:1043-1049. (Pubitemid 350206195)
8. Green RH, Brightling CE, McKenna S, et al, Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial, Lancet 2002; 360:1715-1721. (Pubitemid 35447900)
9. Chlumsky J, Striz I, Terl M, Vondracek J, Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma, J Int Med Res 2006; 34:129-139.
10. Jayaram L, Pizzichini MM, Cook RJ, et al, Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations, Eur Respir J 2006; 27:483-494. (Pubitemid 43372521)
11. Petsky HL, Kynaston JA, Turner C, et al, Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults, Cochrane Database Syst Rev 2007; (2):CD005603.
12. Petsky HL, Cates CJ, Lasserson TJ, et al, A systematic review and metaanalysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils), Thorax 2010 [Epub ahead of print].
13. Rodrigo GJ, Neffen H, Castro-Rodriquez JA, Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review, Chest 2011; 139:28-35.
14. Walker S, Monteil M, Phelan K, et al, Anti-IgE for chronic asthma in adults and children, Cochrane Database Syst Rev 2006; (2):CD003559.
15. Van den Berge M, Pauw RG, de Monchy JG, et al, Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results, Chest 2011; 139:190-193.
16. Flood-Page P, Swenson C, Faiferman I, et al, A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma, Am J Respir Crit Care Med 2007; 176:1062-1071. (Pubitemid 350223751)
17. Haldar P, Brightling CE, Hargadon B, et al, Mepolizumab and exacerbations of refractory eosinophilic asthma, N Engl J Med 2009; 360:973-984.
18. Nair P, Pizzichini MM, Kjarsgaard M, et al, Mepolizumab for prednisonedependent asthma with sputum eosinophilia, N Engl J Med 2009; 360:985-993.
19. Wenzel S, Wilbraham D, Fuller R, et al, Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies, Lancet 2007; 370:1422-1431. (Pubitemid 47576168)
20. Corren J, Busse W, Meltzer EO, et al, A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma, Am J Respir Crit Care Med 2010; 181:788-796.
21. Brightling CE, Berry M, Amrani Y, Targeting TNF-α: a novel therapeutic approach for asthma, J Allergy Clin Immunol 2008; 121:5-10.
22. Wenzel SE, Barnes PJ, Bleeker ER, et al, A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma, Am J Respir Crit Care Med 2009; 179:549-558.
23. Berry MA, Hargadon B, Shelley M, et al, Evidence of a role of tumour necrosis factor alpha in refractory asthma, N Engl J Med 2006; 354:697-708. (Pubitemid 43247140)
24. Nelson HS, Weiss ST, Bleecker ER, et al, The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol, Chest 2006; 129:15-26. (Pubitemid 43265239)
25. Weatherall M, Wijesinghe M, Perrin K, et al, Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy, Thorax 2010; 65:39-43.
26. Hall IP, Blakey JD, Al Balushi KA, et al, Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study, Lancet 2006; 368:771-779. (Pubitemid 44279055)
27. Palmer CN, Lipworth BJ, Lee S, et al, Arginine-16 b2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 2006; 61:940-944. (Pubitemid 44787162)
28. Wechsler ME, Lehman E, Lazarus SC, et al, Beta-adrenergic receptor polymorphisms and response to salmeterol, Am J Respir Crit Care Med 2006; 173:519-526.
29. Bleecker ER, Nelson HS, Kraft M, et al, b2-Receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate, Am J Respir Crit Care Med 2010; 181:676-687.
30. Peters SP, Kunselman SJ, Icitovic N, et al, Tiotropium bromide step-up therapy for adults with uncontrolled asthma, N Engl J Med 2010; 363:1715-1726.
31. Iwamoto H, Yokoyama A, Shiota N, et al, Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype, Eur Respir J 2008; 31:1379-1380.
32. Park HW, Yang MS, Park CS, et al, Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy 2009; 64:778-783.
33. Denning DW, Van Wye J, Lewiston NJ, Stevens DA, Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole, Chest 1991; 100:813-819.
34. Stevens DA, Schwartz HJ, Lee JY, et al, A randomised trial of itraconazole in allergic bronchopulmonary aspergillosis, N Engl J Med 2000; 342:756-762. (Pubitemid 30151919)
35. Wark PA, Hensley MJ, Saltos N, et al, Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial, J Allergy Clin Immunol 2003; 111:952-957. (Pubitemid 36570853)
36. Denning DW, O'Driscoll BR, Hogaboam CM, et al, The link between fungi and severe asthma: a summary of the evidence, Eur Respir J 2006; 27:615-626. (Pubitemid 43372538)
37. Fairs A, Agbetile J, Hargadon B, et al, IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma, Am J Respir Crit Care Med 2010; 182:1362-1368.
38. Denning DW, O'Driscoll BR, Powell G, et al, Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitisation, Am J Respir Crit Care Med 2009; 179:11-18.
39. Crosbie PA, Woodhead MA, Long-term macrolide therapy in chronic inflammatory airway diseases, Eur Respir J 2009; 33:171-181.
40. Kudoh S, Azuma A, Yamamoto M, et al, Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin, Am J Respir Crit Care Med 1998; 157:1829-1832.
41. Richeldi L, Ferrara G, Fabbri LM, et al, Macrolides for chronic asthma. Cochrane Database Syst Rev 2005:CD002997.
42. Simpson JL, Powell H, Boyle MJ, et al, Clarithromycin targets neutrophilic airway inflammation in refractory asthma, Am J Respir Crit Care Med 2008; 177:148-155.
43. Hallstrand TS, Henderson WR Jr, Role of leukotrienes in exercise-induced bronchoconstriction, Curr Allergy Asthma Rep 2009; 9:18-25.
44. Rabinovitch N, Strand M, Stuhlman K, Gelfand EW, Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast, J Allergy Clin Immunol 2008; 121:1365-1371.
45. Lazarus SC, Chinchilli VM, Rollings NJ, et al, Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma, Am J Respir Crit Care Med 2007; 175:783-790. (Pubitemid 46631789)
46. Obase Y, Matsuse H, Shimoda T, et al, Pathogenesis and management of aspirin-intolerant asthma, Treat Respir Med 2005; 4:325-336. (Pubitemid 43127500)